Company news
Beijing Biostar Pharmaceuticals Co., Ltd. Class H (HKEX:2563) news
Beijing Biostar Pharmaceuticals Co., Ltd. Class H news releases on 6ix. Latest, Dec 15, 2025: Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First…
Press releases & updates
Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
December 14, 2025
The FDA Granted Orphan Drug Designation to Biostar Pharma's Utidelone for the Treatment of Pancreatic Cancer
September 25, 2025
Biostar Pharma Successively Achieved First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule (UTD2)
September 15, 2025